Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice DOI Creative Commons
Iwona Piątkowska‐Chmiel, Mariola Herbet, Monika Gawrońska‐Grzywacz

et al.

Psychopharmacology, Journal Year: 2023, Volume and Issue: 240(4), P. 983 - 1000

Published: March 4, 2023

Diabetes causes a variety of molecular changes in the brain, making it real risk factor for development cognitive dysfunction. Complex pathogenesis and clinical heterogeneity impairment makes efficacy current drugs limited. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) gained our attention as with potential beneficial effects on CNS. In present study, these ameliorated associated diabetes. Moreover, we verified whether SGLT2i can mediate degradation amyloid precursor protein (APP) modulation gene expression (Bdnf, Snca, App) involved control neuronal proliferation memory. The results research proved participation multifactorial process neuroprotection. attenuate neurocognitive through restoration neurotrophin levels, neuroinflammatory signaling, Bdnf, App brain diabetic mice. targeting above-mentioned genes is currently seen one most promising developed therapeutic strategies diseases this work could form basis future administration diabetics impairment.

Language: Английский

The relationship between SGLT2 and systemic blood pressure regulation DOI Creative Commons

Priscilla Ahwin,

Diana Martínez

Hypertension Research, Journal Year: 2024, Volume and Issue: 47(8), P. 2094 - 2103

Published: May 23, 2024

Abstract The sodium-glucose cotransporter 2 (SGLT2) is a glucose transporter that located within the proximal tubule of kidney’s nephrons. While it typically associated with kidney, was later identified in various areas central nervous system, including modulating cardiorespiratory regulation like blood pressure. In SGLT2 functions by reabsorbing from nephron’s into bloodstream. inhibitors are medications hinder function SGLT2, thus preventing absorption and allowing for its excretion through urine. not first-line choice, they given conjunction other pharmaceutical interventions to manage hyperglycemia individuals diabetes mellitus. also have surprising secondary effect decreasing pressure independent levels. implication lowering presence system brings question role brain. Here, we evaluate review inhibitors, their control, future as antihypertensive agents, possible mechanisms control system.

Language: Английский

Citations

16
Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study DOI Creative Commons

Mar Garcia-Zamora,

Gemma García‐Lluch, Lucrecia Moreno

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: 206, P. 107295 - 107295

Published: July 4, 2024

The lack of effective treatments for dementia has led to explore the potential antidiabetic agents as a possible approach. This cross-sectional and population-based study aimed investigate relationship between each drug their defined daily doses (DDDs) use anti-Alzheimer's disease (AD) drugs in order establish new hypotheses about role AD. For that purpose, database containing information on medications prescribed 233183 patients aged 50 years or older 2018 2020 was used. DDDs were calculated according ATC/DDD index 2023. Statistical analyses, with logistic regression, carried out assess anti-AD consumption. A total 91836 who at least one antihypertensive, antidiabetic, lipid-modifying agent included study; specifically, 29260 medication. Among agents, glucagon-like peptide-1 analogs (GLP-1) likely have positive association people 70 80 years. Additionally, sodium-glucose cotransporter 2 inhibitors (SGLT2i) prone usage across almost every age. However, insulin associated an increased agents. In conclusion, there is evidence suggesting correlation certain dementia. Specifically, GLP-1 SGLT2i might be lower odds usage, while insulins linked higher using drugs.

Language: Английский

Citations

15
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system DOI Creative Commons
Jiaqi Mei,

Yi Li,

Liyan Niu

et al.

Translational Neurodegeneration, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 9, 2024

The rising prevalence of diabetes mellitus has casted a spotlight on one its significant sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for management, are increasingly studied their benefits. These benefits may include reduction oxidative stress and neuroinflammation, decrease amyloid burdens, enhancement neuronal plasticity, improved cerebral glucose utilization. multifaceted effects the relatively favorable side-effect profile SGLT2 inhibitors render them promising therapeutic candidate disorders. Nonetheless, application impairment is not without limitations, necessitating more comprehensive research to fully determine potential treatment. In this review, we discuss role in neural function, elucidate diabetes-cognition nexus, synthesize current knowledge based animal studies clinical evidence. Research gaps proposed spur further investigation.

Language: Английский

Citations

15
The impact of sodium‐glucose co‐transporter‐2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation DOI

Yun‐Yu Chen,

Hao‐Chih Chang, Yenn‐Jiang Lin

et al.

Diabetes/Metabolism Research and Reviews, Journal Year: 2024, Volume and Issue: 40(2)

Published: Feb. 1, 2024

Abstract Aims The effectiveness of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) on incident dementia in patients with diabetes and atrial fibrillation (AF) remains unknown. This study aimed to investigate the association between SGLT2i risk diabetic AF, explore interactions oral anticoagulants or dipeptidyl peptidase‐4 (DPP4i). Materials Methods We conducted a cohort using Taiwan's National Health Insurance Research Database. Patients AFwithout prior history established cardiovascular diseases, were identified. Using propensity score matching, 810 receiving matched 1620 not SGLT2i. primary outcome was dementia, secondary outcomes included composite events mortality. Results After up 5 years follow‐up, use associated significantly lower (hazard: 0.71, 95% confidence interval: 0.51–0.98), particularly vascular (HR: 0.44, CI: 0.24–0.82). related reduced risks AF‐related hospitalisation 0.72, 0.56–0.93), stroke 0.75, 0.60–0.94), all‐cause death 0.33, 0.24–0.44). protective effects consistent irrespective concurrent non‐vitamin K antagonist (NOACs) DPP4i. Conclusions In hospitalisation, stroke, death. independent either NOACs

Language: Английский

Citations

11
Dapagliflozin ameliorates Lafora disease phenotype in a zebrafish model DOI Open Access
Stefania Della Vecchia, Paola Imbrici, Antonella Liantonio

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 183, P. 117800 - 117800

Published: Jan. 2, 2025

Language: Английский

Citations

1
Neuroprotective effects of empagliflozin against scopolamine-induced memory impairment and oxidative stress in rats DOI Creative Commons
Mahdieh Anoush,

Neda Taghaddosi,

Zahra Bokaei Hosseini

et al.

IBRO Neuroscience Reports, Journal Year: 2025, Volume and Issue: 18, P. 163 - 170

Published: Jan. 10, 2025

Alzheimer's disease (AD) is one of the most common age-related neurodegenerative disorders. The main medicinal theory for management AD belongs to acetyl-cholinesterase-inhibition pathway and NMDA antagonism. Recent investigation proposed memory improvement by sodium-glucose co-transporter 2 (SGLT2) inhibitors which indicated improve glycemic control in adults with type diabetes mellitus. According lack sufficient evidence about efficacy empagliflozin (EMPA) improvement, comparison donepezil (DON), present research was carried out order investigate this hypothesis towards scopolamine-induced neurotoxicity on experimental male Wistar rats. animals divided into two sets, each included 4 groups: first set Healthy [Control, EMPA (4 or 10mg/kg), DON (1mg/kg)]. second rat Alzheimer model, received 2mg/kg Scopolamine intraperitoneal route 10 days followed other treatments [AD, AD+ 10mg/kg) AD+DON]. Normal rats rats, group receiving different substances 8 consecutive 24hours after accomplishment drug administrations, functions assessed through Morris water maze (MWM) paradigm. This task decapitation evaluate biochemical oxidative stress parameters brain tissue. Our data that significantly improved animals' performance behavioral test a significant decrease antioxidant imbalance. In addition, (4mg/kg) reduced both cellular malondialdehyde protein carbonyl content while conversely increased total glutathione content. Besides, levels as well endogenous antioxidants ferric reducing power assay reported be augmented. It seems aspects animal models accordance histopathological assessments. Conclusively, 4mg/kg demonstrated better results all were evaluated during research.

Language: Английский

Citations

1
The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment DOI Creative Commons

Haohui Sun,

Yue Hao, Hao Liu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 11, 2025

Glucagon-like peptide-1 (GLP-1) receptor is widely distributed in the digestive system, cardiovascular adipose tissue and central nervous system. Numerous GLP-1 receptor-targeting drugs have been investigated clinical studies for various indications, including type 2 diabetes obesity (accounts 70% of total studies), non-alcoholic steatohepatitis, Alzheimer's disease, Parkinson's disease. This review presented fundamental information regarding two categories agonists (GLP-1RAs): peptide-based small molecule compounds, elaborated their potential neuroprotective effects by inhibiting neuroinflammation, reducing neuronal apoptosis, ultimately improving cognitive function neurodegenerative diseases. As a new hypoglycemic drug, GLP-1RA has unique role concurrent risk stroke T2D patients. Given infiltration peripheral immune cells into brain tissue, particularly areas surrounding infarct lesion, we further regulatory mechanisms. could not only facilitate M2 polarization microglia through both direct indirect pathways, but also modulate quantity T cell subtypes, CD4, CD8, cells, resulting inhibition inflammatory responses promotion regeneration interleukin-10 secretion. Therefore, believe that "Tregs-microglia-neuron/neural precursor cells" axis instrumental mediating suppression neuroprotection context ischemic stroke. benefits rapid diffusion, favorable blood-brain barrier permeability versatile administration routes, these compounds will be one important candidates GLP-1RA. We look forward to evidence intervention or complicated

Language: Английский

Citations

1
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance? DOI
André Scheen, Fabrice Bonnet

Diabetes & Metabolism, Journal Year: 2023, Volume and Issue: 49(2), P. 101419 - 101419

Published: Jan. 11, 2023

Language: Английский

Citations

21
Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways DOI

Francesca Mancinetti,

Dionysios P. Xenos, Michelantonio De Fano

et al.

Ageing Research Reviews, Journal Year: 2023, Volume and Issue: 90, P. 102018 - 102018

Published: July 20, 2023

Language: Английский

Citations

20
The role of autophagy in the treatment of type II diabetes and its complications: a review DOI Creative Commons
Xuan Zhao,

Luyao Bie,

Dao-Ran Pang

et al.

Frontiers in Endocrinology, Journal Year: 2023, Volume and Issue: 14

Published: Sept. 21, 2023

Type II diabetes mellitus (T2DM) is a chronic metabolic disease characterized by prolonged hyperglycemia and insulin resistance (IR). Its incidence increasing annually, posing significant threat to human life health. Consequently, there an urgent requirement discover effective drugs investigate the pathogenesis of T2DM. Autophagy plays crucial role in maintaining normal islet structure. However, state high glucose, autophagy inhibited, resulting impaired function, resistance, complications. Studies have shown that modulating through activation or inhibition can positive impact on treatment T2DM its it important note specific regulatory mechanisms vary depending target organ. This review explores T2DM, taking into account both genetic external factors. It also provides summary reported chemical traditional Chinese medicine autophagic pathway for

Language: Английский

Citations

19